High Competition Among The Companies, New Product Launches By The Players is Enhancing The Growth of Allergy Immunotherapy Market at The CAGR of 10.8% by 2035

Rising Allergy Prevalence will Positively Impact the Global Allergy Immunotherapy Market at a CAGR of 9.43% during the Forecast Period 2025 to 2035

Market Research Future (MRFR) has published a cooked research report on the “Global Allergy Immunotherapy Market” that contains information from 2025 to 2035. The Allergy Immunotherapy Market is estimated to register a CAGR of 9.43% during the forecast period of 2025 to 2035.

MRFR recognizes the following companies as the key players in the Global Allergy Immunotherapy Market: Novartis, Hal Allergie, Merck Group, Lofarma, Allergopharma GmbH, AstraZeneca, Stallergenes Greer, and Aimmune Therapeutics.

Market Highlights

The Global Allergy Immunotherapy Market is expected to register a CAGR of 9.43% during the forecast period and is estimated to reach USD 7.63 Billion by 2035, up from USD 2.83 Billion in 2024.

This growth is primarily driven by the increasing prevalence of allergic conditions, including asthma, allergic rhinitis, and food allergies, alongside growing awareness of immunotherapy as an effective treatment option. The adoption of personalized immunotherapy programs — such as injectable (subcutaneous) and sublingual treatments — continues to rise globally, supported by growing healthcare expenditure and enhanced patient education on long-term allergy management.

The development of biologic therapies is another key factor shaping the market, as these advanced treatments are gaining regulatory approvals across major regions for managing severe allergic reactions. Furthermore, increasing investments in smart health technologies and digital adherence tracking systems are enabling patients to better manage their treatment regimens, improving overall outcomes.

Government initiatives and regulatory support—such as accelerated approvals by the U.S. FDA for novel immunotherapies—are further boosting market growth, while public health programs are emphasizing allergy awareness and prevention. As personalized medicine advances, allergy immunotherapy is expected to transition toward more targeted, efficient, and patient-centric solutions.

Segment Analysis

The Global Allergy Immunotherapy Market has been segmented based on Type, Product, Indication, Patient Type, and Region.

Based on Type, the market is divided into Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT), and Oral Immunotherapy (OIT).

Among these, Subcutaneous Immunotherapy dominates, valued at USD 2.5 Billion in 2024 and projected to reach USD 5.5 Billion by 2035, owing to its high efficacy and long-term benefits in allergy desensitization.

Sublingual Immunotherapy follows closely, expected to grow from USD 1.8 Billion to USD 4.0 Billion by 2035, driven by patient preference for non-invasive options.

Based on Product, the market includes Allergen Extracts, Biologics, and Conventional Immunotherapy.

Allergen Extracts hold a major share due to their widespread clinical use, while Biologics are emerging as a fast-growing segment with strong R&D pipelines focused on monoclonal antibody therapies.

Based on Indication, the market covers Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, and Food Allergies.

Allergic Rhinitis remains the leading indication, contributing significantly to market revenue, followed by Allergic Asthma and Atopic Dermatitis, reflecting increasing global prevalence and awareness.

Based on Patient Type, the market is segmented into Pediatric, Adult, and Geriatric populations.

The Adult segment dominates due to high exposure to environmental allergens, while the Pediatric segment is expected to expand steadily as early intervention becomes a public health focus.

Region Analysis

By Region, the Allergy Immunotherapy Market is segmented into North America, Europe, Asia Pacific, South America, and the Middle East & Africa.

North America leads the global market, valued at USD 2.35 Billion in 2024, driven by a high allergy prevalence rate, advanced healthcare infrastructure, and strong presence of key industry players.

Europe follows with USD 1.7 Billion in 2024, supported by rising awareness and favorable reimbursement frameworks for allergy treatments.

Asia Pacific is anticipated to experience the fastest growth, reaching USD 0.9 Billion in 2024, due to rapid urbanization, lifestyle changes, and increasing healthcare investments in countries like China and India.

South America and the Middle East & Africa are emerging markets, valued at USD 0.4 Billion and USD 0.36 Billion, respectively, where growing healthcare access and awareness initiatives are opening new opportunities for immunotherapy providers.

Industry Developments

• In October 2023, Aimmune Therapeutics announced positive clinical trial results for its peanut allergy treatment, underscoring the growing acceptance of oral immunotherapy.


• Novartis expanded its allergy treatment portfolio through partnerships with biotech firms to enhance its R&D capabilities.


• Merck Group launched a new line of combination immunotherapy products aimed at improving patient outcomes.


• Stallergenes Greer continues to focus on personalized allergen solutions and improving global access to sublingual immunotherapy.


• Regulatory agencies such as the U.S. FDA and EMA have streamlined approval pathways for allergy immunotherapy products, accelerating innovation and market availability.

Key Findings of the Study

• The Global Allergy Immunotherapy Market is expected to reach USD 7.63 Billion by 2035, growing at a CAGR of 9.43% during the forecast period.


• North America accounted for the largest market share in 2024.


• Subcutaneous Immunotherapy (SCIT) is the dominant segment by Type.


• Allergic Rhinitis represents the leading indication in the market.


• Novartis, Merck Group, Hal Allergie, and Stallergenes Greer are identified as key industry leaders driving product innovation and market expansion.

Future Outlook

The Allergy Immunotherapy Market is poised for substantial growth, driven by the increasing burden of allergic diseases, advancements in biologic treatments, and the adoption of digital tools for patient adherence.

Future opportunities include:

• Developing personalized immunotherapy solutions targeting specific allergens.


• Integrating digital health technologies for remote monitoring and improved treatment compliance.


• Expanding combination therapies to enhance efficacy and patient comfort.


• By 2035, the global market is expected to embrace a patient-centric, precision medicine approach, transforming allergy management and improving quality of life worldwide.

Report Link- https://www.marketresearchfuture.com/reports/allergy-immunotherapy-market-1517